-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Philip Morris International (PM) Undervalued On Its Earnings Beat And Dividend Rise?

Simply Wall St·11/20/2026 18:10:15
Listen to the news

Philip Morris International (PM) just delivered third quarter 2026 results that surpassed earnings estimates, paired with an 8.8% dividend increase to US$1.60 per share and higher full year adjusted earnings guidance.

Despite the upbeat quarter and dividend increase, Philip Morris International’s share price has slipped about 6.7% over the past month and is down roughly 5.2% across the last week, even though the year to date share price return is 16.3% and the 1 year total shareholder return is 24%. This signals that longer term momentum remains intact while near term sentiment cools following ETF selling and leadership changes in its U.S. unit.

Compare Philip Morris International’s earnings beat and dividend move with a hand-picked 8 dividend fortresses that are also leaning on income and resilience to drive total returns.

After a strong quarter, a higher dividend and a pullback to about US$186, Philip Morris International now trades at a double discount to both analyst targets and intrinsic value estimates. How wide is that gap in practical terms for holders today?

Most Popular Narrative: 1% Undervalued

Philip Morris International closed at $186.43 against a narrative fair value of $188.78, which implies only a small valuation gap but a much wider debate over what is driving that price. According to LunaRodas, an investor in the Simply Wall St Community who wrote the narrative, the real tension sits between what management highlights on the call and what it quietly leaves off the table.

Two names are missing from this transcript, and both were load-bearing in the prior conversation.

The first is the modified risk tobacco product authorization for twenty ZYN SKUs. Management had called it the “icing on the cake” of the brand’s U.S. repositioning, the regulatory clearance that let the company market the specific claim that ZYN use carries lower risk than cigarettes across six disease categories. On a call built almost entirely around ZYN, where the brand’s reported numbers outperformed scanner data enough that one analyst (Jefferies’ Andrei Andon) asked for a reconciliation, repeating the question once at Andolina’s request, the authorization does not get a single mention.

See why 5 investors see Philip Morris International as 1% undervalued.

Result: Fair Value of $188.78 (ABOUT RIGHT)

Still, the narrative could crack if regulatory outcomes on ZYN or IQOS shift unfavourably, or if U.S. smoke free investment fails to translate into sustainable profitability.

Find out about the key risks to this Philip Morris International narrative.

Another View on Philip Morris International’s Valuation

The first narrative pegs Philip Morris International as only about 1% below fair value at $188.78. A different lens tells a stronger story. On a P/E of 27.2x, PM trades richer than both global tobacco at 10.9x and its peer average at 25.1x, yet still below a fair ratio of 29.1x. That mix of relative expensiveness on sector terms and discount to the fair ratio points to valuation risk if sentiment normalizes, but also some potential upside if the market applies the higher fair ratio. Which side of that trade-off matters more for you right now?

To see how those earnings multiples stack up in detail, including where PM screens as expensive and where it still looks supported by fundamentals, See what the numbers say about this price — find out in our valuation breakdown.

NYSE:PM P/E Ratio as at Nov 2026
NYSE:PM P/E Ratio as at Nov 2026

Next Steps

Mixed signals on Philip Morris International so far. If you want to move from headline takeaways to your own conviction, consider weighing up the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Philip Morris International?

If you only stop at Philip Morris International, you miss a broader set of opportunities where quality, yield and risk control can reshape your portfolio’s outcomes.